Enhancing Downstream Processing of Biologics or Gene Therapies

Vinit Saxena, Salah Ahmed, Naveen Kumar Singh
  • Genetic Engineering & Biotechnology News, April 2019, Mary Ann Liebert Inc
  • DOI: 10.1089/gen.39.04.17

Enhancing Downstream Processing of Biologics or Gene Therapies

What is it about?

Sepragen’s single-use chromatography systems can purify biologics or gene therapy products while accommodating input from smaller bioreactors

Why is it important?

As productivities have improved and more niche markets and biosimilars have emerged, the age of mega-sized stainless-steel single-product plants has waned. On the rise are smaller, more targeted plants for niche markets or, increasingly, multiproduct plants.

Perspectives

Dr Naveen Kumar Singh
University of Notre Dame

Single-use chromatography systems are starting to take hold among manufacturers of biologics such as monoclonal antibodies (mAbs). As biotechnology evolves, these systems, like other single-use systems adapted for mAb production, need to be modified to help them satisfy the specific requirements of new applications.

Read Publication

http://dx.doi.org/10.1089/gen.39.04.17

The following have contributed to this page: Dr Naveen Kumar Singh